Simplifying Global Compliance
Amgen Unveils Biosimilar Plans Amid Questions of Brand-Drug Bullying
Amid accusations of follow-on biologic blocking, Amgen has unveiled plans to develop half a dozen biosimilar products by 2017 as part of its long-term global growth strategy.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing